EUCTR2007-004232-22-DK进行中（未招募）1 期
Phase II study with cetuximab, irinotecan and sunitinib (CIS) for patients with treatment resistant colorectal cancer
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Phase II trial with Cetuximab and Irinotecan (CetIri) for patients with platinum resistant esofagus- or gastric cancer - CetIriPatients with esofagus- and gastric cancerMedDRA version: 9.1Level: LLTClassification code 10017758Term: Gastric cancerEUCTR2008-006168-12-DKOdense University Hospital55
已完成
2 期
Phase II study of cetuximab plus irinotecan for unresectable colorectal cancernresectable advaned or recurrent colorectal cancerJPRN-UMIN000001838Aichi Cancer Center Hospital30
进行中（未招募）
不适用
Phase II study of therapy with Cetuximab and Irinotecan every second week to Irinotecan resistant patients with metastatic colorectal cancer-effect and biological markersIn Denmark there is approximately 3600 new cases of Colorectal cancer every year. In Denmark about half of these patients will eventually develop metastatic disease. In Denmark it is suggested that 150 patients each year will be in such good performance to third line chemotherapy.MedDRA version: 9Level: 1.0Classification code 10010029EUCTR2006-001961-40-DKDepartment of Oncology, University Hospital Herlev100
已完成
2 期
Phase II study of biweekly cetuximab+irinotecan therapy for unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000011362Osaka City University20
进行中（未招募）
不适用
A phase II trial with cetuximab, bevacizumab and irinotecan for patients with malignant glioblastomas and progression after radiation therapy and temozolamid - CBI-GBMRecurrent or progressive primary GBM in patients with performance status (PS) 0-2.EUCTR2006-000182-10-DKRigshospitalet, Finsen Center32